Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

SEATTLE, Wash., Nov. 7, 2013 /PRNewswire/ --

  • Received $17.4 million in cash in October 2013
  • Total operating expenses in 3Q 2013 were $13.6 million including $3.2 million in non-cash expenses compared to $13.3 million including non-cash expenses of $2.1 million in 2Q 2013
  • U.S. and European regulators accepted Omeros' OMS302 marketing applications for review
  • OMS824 and OMS721 Phase 1 clinical programs generated positive data
  • Increased the number of unlocked orphan GPCRs to 52
  • Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2013.

    "Throughout the third quarter of 2013, we continued to make significant strides in development across our pipeline," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "For OMS302, the marketing applications were accepted for review by both the FDA and EMA, and the market launch is planned for the second half of 2014. Our OMS824 program for the treatment of cognitive disorders was granted orphan drug designation by the FDA, generated positive Phase 1 clinical trial results, began enrollment in a Phase 2 trial in patients with schizophrenia and is now initiating a Phase 2 trial in Huntington's disease. OMS721, our MASP-2 inhibitor, entered a Phase 1 clinical trial from which we reported positive data today, and a Phase 2 trial to evaluate the molecule's efficacy and safety in patients with thrombotic microangiopathies is planned for early 2014. Preclinically, our GPCR platform continued to identify functionally active compounds against an
    '/>"/>

    SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
    2. Omeros to Present at the 12th Annual Needham Healthcare Conference
    3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
    5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
    6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
    7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
    8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
    9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
    10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
    11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/21/2015)... 21, 2015 A leading manufacturer of ... slated to discuss its custom fabrication services today at ... website, which launched just prior to the INTERPHEX event. ... 21, 22 and 23) at the Javits Center in ... the world’s largest and most innovative pharmaceutical and biotech ...
    (Date:4/20/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) (DelMar and the Company), a ... cancer therapies in new orphan drug indications, today ... Annual Meeting of the American Association for Cancer ... for its lead product candidate VAL-083 ...
    (Date:4/20/2015)... Calif. , April 20, 2015 PointCross ... Pvt. Ltd. to provide an integrated Big Data and ... all biomarkers collected in the context of clinical trials ... of precise or multi-targeted drug candidates, stratified patient selection ... disease progression free survival. Highlighting the ...
    (Date:4/20/2015)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC ... announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd. ... one of its proprietary human-derived CPP sequences and a ... of NFkB signalling even if administered when the BBB ... blood brain barrier (BBB) in mice was studied and ...
    Breaking Biology Technology:HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3
    ... WILMINGTON, Delaware, November 3 ... Advanced Technologies Market, (2009 - 2014),published by MarketsandMarkets ... global stem cell market. It identifies and analyzes,the ... various,products, services, technologies, and applications submarkets in different,geographic ...
    ... has won a $4.4 million grant from the ... (ARPA-E) to lead a multidisciplinary, multi-institutional research project ... magnets. Stronger magnets are essential for increasing ... and communications systems in the 21st-century, and for ...
    ... The World Egg Bank (TWEB), an international ... announced a first-of-its-kind partnership with a European fertility clinic to ... of donated frozen eggs at or less than the cost ... is between TWEB and IVI in Alicante, Spain, the world,s ...
    Cached Biology Technology:MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 3UD wins $4.4 million to develop next-generation magnets 2World Egg Bank Launches Medical Tourism Program With World's Largest Egg-Donation Fertility Clinic 2
    (Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
    (Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
    (Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
    Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
    ... Short courses of antibiotics can leave normal gut bacteria ... after treatment, say scientists writing in the latest issue ... The researchers believe that this reservoir increases the chances ... their survival and suggesting that the long-term effects of ...
    ... seen as a triumph for the preservation of nature, yet ... world,s largest protected areas encompass vast amounts of wilderness but ... or include unusually large numbers of birds, amphibians, or mammals, ... BioScience . The study, by Lisette Cant-Salazar and Kevin ...
    ... researchers have shown how a protein called perforin punches holes ... of the mechanism of this assassin is published today in ... weapon of cleansing and death," says project leader Prof James ... have been hijacked by viruses or turned into cancer cells ...
    Cached Biology News:Antibiotics have long-term impacts on gut flora 2How do we kill rogue cells? 2
    ... Hot Start Taq ... activity before the onset ... nonspecific amplification and primer-dimer ... is raised, the antibody ...
    ... Fluorescein 6-Fam, Hex, Tet Cy3, Cy5, ... Tamra Black Hole Quenchers Molecular Beacons* ... Tamra, Joe 3 Dabcyl Dabcyl*Licensed ... York Double labelled probes are purified either ...
    ... (rEK) is a highly purified preparation of ... serine protease which recognizes the identical cleavage ... has similar enzymatic activity (1). Novagen&'s enzyme ... to yield the highest activity available, and ...
    Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
    Biology Products: